Drug Trial Radar · NCT06245330
A Phase I/II Study of AST-001 in Subjects With Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Feb 7, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
180
Planned (sponsor's estimate)
Start
Jul 7, 2022
Primary completion
Aug 31, 2027
Study completion Aug 31, 2027
Sponsor
- Lead sponsor
- Ascentawits Pharmaceuticals, LtdIndustry
- Sponsor type
- Industry
- First posted
- Feb 7, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A first-in-human open-label, Phase I/II study to evaluate the safety, tolerability, MTD/RP2D, PK, and preliminary efficacy of AST-001 administered as a single agent.
Conditions
- Solid Tumor
- Pancreatic Cancer
Interventions
AST-001Drug
liquid formulation for Intravenous infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence and severity of adverse events (AEs)Time frame: Adverse events will be noted as it occurs. Timeframe for measure begins after informed consent until 30 days after last dose of study drug.
- Assess safety changes in electrocardiogram (ECG)Time frame: Day 1 of each cycle(there are 26 cycles; 28 days for each cycle)
- Assess safety changes of body weight.Time frame: pre-AST-001 infusion of each cycle (there are 26 cycles; 28 days for each cycle)
- Number of participants with dose limiting toxicities (DLTs)Time frame: Throughout Cycle 1 (28 days for each cycle)
- Define the Recommended Phase 2 Dose (RP2D)Time frame: Days 1, 8 and 15 of each cycle (all 26 cycles and there are 28 days for each cycle)
- Pharmacokinetics (PK) - Time to maximum concentration (Tmax)Time frame: Days 1 and 15 of Cycle 1 (first cycle of 26 cycles and there are 28 days for each cycle)
- PK - Maximum peak plasma concentration (Cmax)Time frame: Days 1 and 15 of Cycle 1 (first cycle of 26 cycles and there are 28 days for each cycle)
- PK - Area under the concentration-time curve (AUClast) PK - Area under the concentration-time curve (AUClast)Time frame: Days 1 and 15 of Cycle 1 (first cycle of 26 cycles and there are 28 days for each cycle)
- PK - Half-life (T1/2)Time frame: Days 1 and 15 of Cycle 1 (first cycle of 26 cycles and there are 28 days for each cycle)
- Efficacy: Objective response rate(ORR)Time frame: up to 26 cycles (there are 28 days for each cycle)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Jinlin Cancer Hospital
Changchun, Jinlin, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.